TAK News and Press, Takeda Pharmaceutical Company Limited American Depositary Shares From 06/27/24

2024-06-27 16:48:49 ET Summary The small biotech sector has badly underperformed the major market indices so far in 2024. However, that could change as the Federal Reserve cuts interest rates and/or M&A deal volume picks up across the industry. Today, we highlight three sm...

Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting and at the Audit and Supervisory Committee meeting, following the 148th Ordinary Meeting of Shareholders, held in Osaka today. Takeda's Board of Directors has 11 members servi...

2024-06-25 08:13:12 ET More on Takeda, Wave Life Sciences, etc. Takeda: Strong Growth Catalysts And Maturing Pipeline Continue To Limit Downside Risk Takeda Pharmaceutical Company Limited (TAK) Fiscal Year 2023 Earnings Call Transcript Wave Life Sciences Ltd. (WVE) Q...

2024-06-24 11:58:27 ET More on Takeda Pharmaceutical Takeda: Strong Growth Catalysts And Maturing Pipeline Continue To Limit Downside Risk Takeda Pharmaceutical Company Limited (TAK) Fiscal Year 2023 Earnings Call Transcript Takeda Pharmaceutical Company Limited 2023...

LIVTENCITY Is the First and Only Post-Transplant Anti-CMV Treatment Approved in Japan That Targets/Inhibits UL97 Protein Kinase 1 CMV Is One of the Most Common and Serious Post-transplant Infections and Can Lead to Secondary Infections and Serious Consequences, Including Loss of Trans...

2024-06-24 01:43:14 ET Summary Astria Therapeutics stock has fallen 40% since early 2023, but promising early data for its candidate STAR-0215 in treating HAE is helping drive analyst Buy ratings. ATXS stock has a compound called STAR-0310 in development for an immune disorder, wi...

2024-06-23 11:13:33 ET Summary Since the publication of my last article, Pfizer has continued to surprise me pleasantly. In early May, Pfizer published financial results for the first quarter of 2024, which were enthusiastically received by Wall Street. On June 14, 2024, the c...

Mezagitamab-Treated Patients Showed Rapid and Sustained Increases in Platelet Counts That Persisted 8 Weeks After the Last Dose Through to Week 16 1 Mezagitamab Had a Favorable Safety Profile, with No New Safety Signals 1 Takeda Plans to Initiate Gl...

2024-06-21 16:33:06 ET More on Takeda Pharmaceutical Takeda: Strong Growth Catalysts And Maturing Pipeline Continue To Limit Downside Risk Takeda Pharmaceutical Company Limited (TAK) Fiscal Year 2023 Earnings Call Transcript Takeda Pharmaceutical Company Limited 2023...

− Approval Based on Results from Positive, Global, Phase 3 FRESCO-2 Trial − FRUZAQLA (fruquintinib) is the First Novel Targeted Therapy in the EU for Metastatic Colorectal Cancer (mCRC) Regardless of Biomarker Status in Over a Decade Takeda ( TSE:4502/N...